Milurit

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Milurit

Property Description
Active Ingredient Allopurinol
Form Tablet (Oral), Solution (Intravenous)
Pharmacological Class Xanthine Oxidase Inhibitor
Common Use Reduction of high Uric Acid levels
Origin Synthetic

Milurit: Identity, Active Ingredient, and Origin

Milurit is a brand designation for a medicine containing the sole active ingredient, Allopurinol, a synthetic pharmaceutical compound that is chemically related to the natural purine base hypoxanthine. This compound is the definitive urate-lowering medication within this brand. While Milurit is the brand name, Allopurinol is also marketed globally under other names, such as Zyloprim, and is widely available generically. The drug is administered via the oral route as a tablet and, for specific acute clinical needs, as a sterile solution for injection administered via the intravenous route. Its essential status is recognized, with its inclusion on the WHO Model List of Essential Medicines.


Pharmacological Classification and General Purpose

Allopurinol belongs to the Xanthine Oxidase Inhibitor pharmacological class, a mechanism that is clinically recognized for its effectiveness in addressing hyperuricemia. This classification directly informs the drug's core prophylactic purpose: to reduce the overall systemic burden of uric acid. The medication is typically utilized in scenarios where the body is overproducing uric acid, such as in patients undergoing certain forms of chemotherapy, where rapid cell turnover creates excessive purine metabolites. It maintains a foundational role in maintaining uric acid concentrations within a healthy, non-pathological range.


Understanding Allopurinol’s Action (High-Level)

The mechanism principle of Allopurinol is based on targeted enzyme blocking. The molecule acts as a structural analogue that selectively inhibits the enzyme xanthine oxidase, thereby blocking the final stages of the purine catabolism pathway. This action prevents the conversion of precursors into uric acid. The direct benefit is a measurable reduction in the production of uric acid by the body, offering foundational control over the metabolic process that generates this metabolite and minimizing the risk associated with persistently elevated levels.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Milurit?

Possible Side Effects and Safety Information

The safety profile of Milurit (allopurinol) is classified by regulatory authorities based on the frequency and system-organ class of documented adverse reactions. The most common adverse effects listed in official documents are related to the Skin and Subcutaneous Tissue Disorders, appearing as a skin rash, and Gastrointestinal Disorders, including nausea and vomiting.


Serious Adverse Reactions and Safety Constraints

The most clinically significant safety concern involves rare but potentially fatal severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which are forms of generalized hypersensitivity syndrome. If a rash or any other sign of a hypersensitivity reaction appears, regulatory labeling mandates immediate discontinuation of the medicine.

Serious adverse reactions also involve the Blood and Lymphatic System, including agranulocytosis and aplastic anaemia, and potential Hepatotoxicity and Nephrotoxicity.


Time-Related and Population-Specific Considerations

Official safety information notes time-related patterns, such as the potential for acute gout attacks to be precipitated during the initial stages of treatment. The risk for SCARs is often reported to be highest within the first few months of therapy.

Specific population considerations exist for patients with renal impairment, who require reduced doses due to the increased risk of adverse effects. Furthermore, the presence of the *HLA-B5801 allele** is officially associated with an elevated risk of severe hypersensitivity syndrome, particularly in certain Asian populations.

Overdose and Emergency Response

Milurit Overdose and when to seek help

In the event of acute massive ingestion of Milurit (allopurinol), regulatory information states that initial manifestations may include severe gastrointestinal distress such as nausea, vomiting, diarrhea, and abdominal pain.

The most severe documented outcomes requiring immediate action are the potentially life-threatening systemic reactions, specifically Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms). These conditions are associated with multi-organ involvement, including the hepatic and renal systems.

Urgent Help-Seeking Requirements

Action Mandated by Regulators Requirement
Immediate Medical Attention Must be sought for suspected overdose or the onset of a skin rash, fever, or any sign of a severe allergic reaction.
Drug Discontinuation The medicine must be withdrawn immediately at the first appearance of a rash or other evidence of sensitivity.

Official Management and Clearance

Regulatory documents confirm that treatment for overdose is symptomatic and supportive. It is officially stated that no specific antidote is known for allopurinol. Both the drug and its main metabolite, oxipurinol, are known to be removable by renal dialysis. Patients with impaired renal function are noted to be at an increased risk of severe toxicity because of the retention of the drug and its prolonged presence in the body.

Therapeutic Uses of Milurit

What Milurit Treats: Main Uses and Benefits

Milurit (allopurinol) is commonly used to help with certain distressing symptoms applied across domains where additional symptomatic support is needed. This medication is relevant in contexts marked by increased discomfort or tension across several core symptomatic domains, including the management of recurrent gout attacks, the prevention of uric acid-related kidney stones, and the reduction of uric acid spikes during cancer therapy. It is used for managing conditions characterized by periods of heightened symptoms.

The therapy is applied when conditions produce significant symptomatic burden, particularly when symptoms interfere with daily functioning. The primary therapeutic role is to offer symptomatic relief that helps patients cope more steadily with difficult episodes and supports general well-being during symptomatic phases. This is commonly used across conditions presenting with acute episodes where short-term symptomatic assistance is needed.

Quick Fact: Focus on Episodic Symptom Management Milurit provides support that helps ease the overall symptom burden associated with inflammatory or irritative states and assists with maintaining functional stability during periods of heightened symptoms.

Eligibility and Restrictions for Use

Who Can and Cannot Use Milurit? (Allopurinol)

The eligibility profile for Milurit is strictly defined by official regulatory documentation, outlining populations who are approved for use, those for whom use is restricted, and those for whom it is absolutely contraindicated.


Contraindications and Restrictions

Classification Population/Condition Regulatory Status
Absolute Contraindication Known hypersensitivity to allopurinol or any excipient Prohibited
Breast-feeding women Contraindicated
Use Not Recommended Patients carrying the *HLA-B58:01 allele** (common in specific Asian populations) Requires caution/avoidance
Asymptomatic hyperuricemia (mild elevation of uric acid) Not Recommended

Age and Physiological Limitations

  • Adults are the standard approved population for use.
  • Pediatric use is generally not established and is restricted to children with hyperuricemia secondary only to specific conditions such as malignancy or Lesch-Nyhan syndrome.
  • Patients with existing renal impairment or hepatic impairment require use with caution and close monitoring, as these conditions affect how the body processes the medicine.
  • Use during pregnancy is permitted only if clearly indicated and after careful consideration of potential risks versus clinical benefits, according to official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Milurit (allopurinol) has officially documented interaction patterns that primarily derive from its ability to inhibit the enzyme xanthine oxidase. This results in significant restrictions and pharmacokinetic outcomes when co-administered with certain medications, as stated in regulatory prescribing information.


Documented Interaction Restrictions

Category Interacting Medicine Official Regulatory Statement
Contraindicated Combination Pegloticase Therapy must be discontinued and not instituted during co-treatment.
Avoid Concomitant Use Capecitabine Formal instruction in regulatory documents to avoid combination.
Increased Exposure Mercaptopurine, Azathioprine Requires mandatory dose reduction of the co-drug due to increased systemic exposure.

Additive Pharmacodynamic Risks

Co-administration with certain drug classes results in an officially described increased risk of specific adverse effects. Thiazide diuretics and ACE inhibitors may increase the risk of hypersensitivity reactions, which is heightened in patients with decreased renal function. Concomitant use with Ampicillin or Amoxicillin is associated with an increased incidence of skin rash. Furthermore, administration with certain Cytotoxic Agents may increase the risk of myelosuppression, and the effects of Warfarin may be enhanced, requiring reassessment of prothrombin time.

Administration Timing Rule

For chemotherapy regimens intended to prevent tumor lysis syndrome, allopurinol treatment must be initiated 24 to 48 hours before the cytotoxic therapy begins.

Mechanism of Action

Targeted Inhibition of Uric Acid Production

Milurit's mechanism of action involves the precise inhibition of the enzyme Xanthine Oxidoreductase (XOR), a key catalyst in the breakdown of purine bases. The drug is first converted into its active metabolite, Oxypurinol, which functions as a structural analogue. Oxypurinol then binds tightly to the enzyme's active site, forming a stable complex that effectively blocks XOR function. This blockade directly limits the synthesis of Uric Acid from its precursors, Hypoxanthine and Xanthine.


Dual Modulation of Purine Metabolism

By halting the conversion of precursors, the drug simultaneously modulates two pathways. It causes the less soluble Uric Acid to be replaced by the more soluble purines, which are readily excreted by the kidneys. This precursor diversion also engages the purine salvage pathway, indirectly limiting the de novo creation of new purine molecules and contributing to a decreased purine metabolic load. This modulation influences the systemic purine economy.


Causal Cascade to Urate Concentration Reduction

This enzyme inhibition results in a significant reduction of circulating Monosodium Urate (Uric Acid) in the blood plasma. Maintaining the plasma concentration below its saturation threshold creates a concentration gradient that promotes the dissolution of pre-existing urate crystal deposits from tissues, promoting the establishment of an environment with low urate concentration.

Dosage and Administration Information

Official Administration Protocols for Milurit

Milurit (allopurinol) is administered through specific methods, dosage schedules, and conditions. The medicine is available in two approved routes of administration: as an oral tablet and as a powder for injection for intravenous use.


Dosage Forms and Standard Regimens

Administration Route Standard Adult Dose (Gout/Stones) Maximum Daily Dose (Oral)
Oral Tablet Initial: 100 mg once daily. Titrated in 100 mg weekly increments. 800 mg or 900 mg
Intravenous (IV) 200 mg/m^2/day to 400 mg/m^2/day (for specific high-urate conditions) 600 mg

Key Usage Conditions and Adjustments

  • Timing: Oral doses are advised to be taken after a meal to improve gastrointestinal tolerability. If the total daily dose exceeds 300 mg, it should be administered in divided doses.
  • Hydration: Patients must maintain adequate fluid intake to ensure a daily urinary output of at least 2 liters.
  • Duration: For gout management, use is typically long-term. For hyperuricemia associated with cancer therapy, treatment should be initiated 24 to 48 hours prior to chemotherapy and discontinued once the risk is resolved.
  • Renal Impairment: Dosing requires reduction based on the degree of renal function impairment. For those with severely impaired function (Creatinine Clearance < 10 mL/min), a maximum dose of 100 mg daily or less frequently is recommended.
  • IV Preparation: The 500 mg powder for injection must first be reconstituted with 25 mL of sterile water before being further diluted for infusion; the final solution concentration must not exceed 6 mg/mL.

Recent Clinical Evidence

Research evidence / Overview of Studies for Milurit (Allopurinol)


Evidence for Use in Managing Recurrent Gout Attacks

A substantial body of research has explored the use of this medicine in managing gout, relying on Randomized Controlled Trials (RCTs), supported by systematic reviews and long-term observational data. These studies were conducted to examine how the medicine influences blood uric acid concentrations in adults with chronic gout, a condition characterized by fluctuating or episodic manifestations. Researchers monitored several outcomes related to systemic or functional imbalance, including changes in the concentration of serum uric acid (SUA), the frequency of acute gout flares, and the changes observed in the size of urate deposits (tophi).

Studies consistently reported data showing patterns related to SUA concentration measurements, frequently noting that participants achieved and maintained targeted levels of uric acid throughout the study periods. Further analyses of the data research describes patterns where adherence to the treatment regimen was observed in some studies to correlate with outcomes describing episodic or acute changes over time. What remains uncertain often relates to how findings translate outside of research settings, where variability exists in whether individuals consistently reach and maintain the target SUA goal in non-trial settings.


Evidence for Use in Preventing Tumor Lysis Syndrome

Research for this medicine's use in preventing rapid uric acid spikes during cancer therapy primarily involves historical studies and open-label clinical trials. These studies were conducted in research settings involving temporary physiological imbalance, which are applied in research contexts involving fluctuating or unstable symptoms. The research examined outcomes capturing phases of heightened symptom activity, such as the maximum level of uric acid in the blood achieved during the critical post-treatment period and the maintenance of renal function markers.

Studies consistently described that initiating the treatment prior to chemotherapy data show patterns related to changes in serum uric acid concentrations when compared to untreated groups. Modern comparisons are mainly structured against newer uric acid-lowering agents, rather than against no intervention, due to established care practices.


What is Still Uncertain and Research Gaps

While much is known about the medicine’s influence on uric acid levels, several areas remain uncertain. Long-term effects on major health events like heart attack or stroke in people who have elevated uric acid but do not have gout are not fully established. Recent large RCTs monitoring cardiovascular outcomes reported no significant difference compared to placebo, meaning certainty remains low in this area. Additionally, the evidence base for clinical outcomes in special populations, such as for slowing kidney disease progression in patients with chronic kidney disease (CKD) who do not have gout, is limited, and data for certain subgroups remain insufficient.

Key Studies & References

  1. NICE Guideline NG219: Chronic kidney disease: assessment and management

Frequently Asked Questions (FAQ)

Common questions about Milurit (FAQ)


Q: Does Milurit completely cure gout, or is it a long-term management treatment?

Milurit is officially indicated for the management of the signs and symptoms of gout. For this purpose, the treatment is typically considered to be a long-term therapy designed to help lower and maintain consistent uric acid levels.


Q: Is it common to take Milurit for the rest of one's life?

Regulatory documents indicate that treatment for conditions like chronic gout and recurrent calcium oxalate kidney stones is usually a long-term therapy. The duration of use is typically determined by the persistence of the underlying condition requiring ongoing uric acid management.


Q: What are the inactive ingredients or excipients contained in Milurit tablets?

The official product information lists the inactive ingredients, also called excipients, in the tablets. These typically include substances such as lactose monohydrate, colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose.


Q: Can Milurit help prevent kidney stones that aren't related to gout?

Official labeling states that this medicine is indicated for managing a specific type of kidney stone: recurrent calcium oxalate calculi. This use is primarily for adult patients who have high daily uric acid excretion that has not responded to other standard therapies.


Q: Do the benefits of Milurit stop if the medicine is temporarily stopped?

As an inhibitor of uric acid production, the effects of the medication are generally linked to its presence in the body. If the medication is stopped, serum uric acid levels may increase again, which is associated with the risk of recurrent gout attacks.


Q: How long does it typically take to feel the full effects of Milurit?

The onset of action, which is when the medicine begins to work, occurs within two to three days. However, the full peak effects on uric acid levels may take approximately one week. The full effect is typically achieved over time, and regular monitoring is used to determine if the desired uric acid level is reached.


Q: How long after starting Milurit can I expect the number of gout attacks to decrease?

It is noted in official warnings that a patient may initially experience an increase in gout attacks during the first few months of treatment. A decrease in the frequency of attacks is typically observed as a long-term effect. The actual time frame for this outcome can vary among patients.


Q: Does Milurit frequently cause stomach issues like nausea or diarrhea?

Yes, regulatory documents list gastrointestinal disorders among the most common adverse effects. These frequently reported side effects include nausea, vomiting, and diarrhea.


Q: Can Milurit affect liver function over time?

Cases of reversible hepatotoxicity, which is damage to the liver, have been reported in official documents. Official safety information indicates that if signs or symptoms of liver trouble develop, monitoring of liver function may be necessary.


Q: Are there long-term side effects associated with continuous use of Milurit?

Serious adverse reactions that may be a concern over time include potential issues with kidney function (nephrotoxicity), liver function (hepatotoxicity), and suppression of blood cell production (myelosuppression). These systems may require ongoing monitoring.


Q: Is it recommended to avoid or strictly limit alcohol consumption while taking Milurit?

Official information suggests that avoiding or limiting alcohol consumption may be appropriate. Alcohol can potentially increase drowsiness or other nervous system side effects and may also contribute to elevated serum uric acid levels.


Q: What foods or drinks should be limited while taking Milurit?

Patient counseling information suggests that following a special diet, such as one that limits high-purine foods, is a part of managing the condition. General advice also emphasizes adequate fluid intake.


Q: Does Milurit change the effects of blood thinning medications?

Official drug interaction reports state that Milurit may inhibit the breakdown of the blood thinner warfarin. This can potentially enhance the anticoagulant (blood-thinning) effect of warfarin. The use of both medications may require increased monitoring.


Q: Can Milurit be used safely by individuals who have severe liver disease?

Official safety information states that the medicine must be used with caution in patients with any degree of hepatic impairment (liver damage). Official safety information indicates that close monitoring may be recommended for these patients due to the increased risk of liver damage.


Q: Is Milurit considered a first-line therapy compared to other uric acid-lowering drugs like febuxostat?

Current clinical guidelines often recommend Milurit as the first-line agent for the prevention of gout in patients who require urate-lowering therapy and do not have specific contraindications to its use.


Q: Does Milurit have the potential to cause hair loss?

Official side effect listings indicate that hair loss or thinning of the hair (alopecia) has been reported as a documented side effect of the medicine.


Q: Is a metallic taste in the mouth a known side effect of Milurit?

Yes, a change in the sense of taste, including the reporting of a metallic taste, is included in the list of known side effects for this medication.


Q: Can Milurit cause an increase in breast size (gynecomastia)?

Swelling of the breasts or breast soreness, known as gynecomastia (in males) and breast enlargement (in females), has been reported in official product information as an adverse effect.


Q: Does Milurit make a person more susceptible to infections or easy bruising?

The medication has been associated with bone marrow suppression, which can lead to low blood cell counts. This condition can increase the patient’s risk of infection or cause unusual bleeding and bruising.


Q: Is feeling dizzy or drowsy a reported side effect that could affect driving or operating machinery?

Drowsiness, somnolence, and dizziness have been reported in official warnings. Because these effects have been reported, caution is recommended before performing tasks that require concentration, such as driving or operating machinery.


Q: Does Milurit contain lactose or any other common allergens?

Based on the regulatory documents for its tablets, Milurit contains lactose monohydrate as an inactive ingredient. Patients who have known allergies to any component may benefit from reviewing the full ingredient list.


Q: Does the use of herbal supplements need to be discussed with a doctor when taking Milurit?

Yes, official patient counseling recommends sharing information with a healthcare provider or pharmacist about all other medications being taken. This includes herbal remedies, vitamins, or any supplements, as potential interaction effects may not be known.


Q: Are there any known effects of Milurit on fertility?

According to regulatory patient information, there is currently no established evidence to suggest that taking this medication will reduce or negatively affect fertility in either men or women.


Q: Is it normal to feel generally unwell (malaise) when first starting the medication?

Feeling generally unwell (malaise), fever, and chills have been reported, particularly when they occur in conjunction with a potential severe hypersensitivity or toxic reaction. Official information notes that signs of a severe reaction should be brought to a healthcare provider's attention.

How should Milurit be stored and disposed of?

How to Store and Dispose of Milurit (Allopurinol)

Official regulatory guidelines define specific storage and disposal requirements for Milurit (allopurinol) to maintain stability and ensure safety.

Storage Requirements

Milurit tablets must be stored at a temperature not exceeding 25°C and must be kept in the original container, which should remain tightly closed to protect the medicine from moisture. It is mandatory that the product is not frozen and is stored out of sight and reach of children.

Disposal Instructions

Milurit is not on the FDA's flush list. Unused or expired medication should ideally be taken to a drug take-back location or mail-back program. If household disposal is necessary, the medicine must be removed from its container, mixed with an undesirable substance (e.g., dirt or coffee grounds), sealed in a bag, and then placed in the trash. The empty packaging should have all personal information scratched out before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Milurit found in:

A-Z Index: